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Abstract
Background: Glaucoma is an age-related neurodegenerative disorder involving the loss of retinal ganglion cells
(RGCs), which results in blindness. Studies in animal models have shown that activation of inflammatory processes
occurs early in the disease. In particular, the complement cascade is activated very early in DBA/2J mice, a widely
used mouse model of glaucoma. A comprehensive analysis of the role of the complement cascade in DBA/2J
glaucoma has not been possible because DBA/2J mice are naturally deficient in complement component 5
(C5, also known as hemolytic complement, Hc), a key mediator of the downstream processes of the complement
cascade, including the formation of the membrane attack complex.
Methods: To assess the role of C5 in DBA/2J glaucoma, we backcrossed a functional C5 gene from strain C57BL/6J
to strain DBA/2J for at least 10 generations. The prevalence and severity of glaucoma was evaluated using ocular
examinations, IOP measurements, and assessments of optic nerve damage and RGC degeneration. To understand
how C5 affects glaucoma, C5 expression was assessed in the retinas and optic nerves of C5-sufficient DBA/2J mice,
using immunofluorescence.
Results: C5-sufficient DBA/2J mice developed a more severe glaucoma at an earlier age than standard DBA/2J
mice, which are therefore protected by C5 deficiency. Components of the membrane attack complex were found
to be deposited at sites of axonal injury in the optic nerve head and associated with RGC soma in the retina.
Conclusion: C5 plays an important role in glaucoma, with its deficiency lessening disease severity. These results
highlight the importance of fully understanding the role of the complement cascade in neurodegenerative
diseases. Inhibiting C5 may be beneficial as a therapy for human glaucoma.
Introduction
Glaucoma, the second leading cause of blindness world-
wide, is a neurodegenerative disease involving the death
of retinal ganglion cells (RGCs) and degeneration of the
optic nerve [1-3]. Major risk factors include aging and
increased intraocular pressure (IOP). A number of pro-
cesses have been implicated in glaucoma, but the key
molecules that mediate early damage remain unclear.
Upregulation and activation of complement proteins are
consistent features of human glaucoma and animal
models of glaucoma [4-7]. Despite the importance of the
complement cascade, the exact roles of specific pathway
members in glaucoma have not been determined.
The complement cascade is activated as part of an in-
nate immune response against pathogens. It also serves
to clear unwanted cells and cellular debris [8], and has
been shown to mediate synapse elimination in the cen-
tral nervous system (CNS) [9]. Three major variants of
the complement cascade have been widely studied: the
classical, the alternative, and the lectin pathways. A
major effector molecule of all three pathways is comple-
ment component C5 [10]. The C5 protein is cleaved by
C5 convertases to produce C5a and C5b peptides. C5a is
an anaphylotoxin that can mediate neuroinflammatory
responses, while C5b is a key molecule in the formation
of the membrane attack complex (MAC). The MAC is a
transmembrane channel composed of the complement
factors C5b, C6, C7, C8, and C9 (C5b-9) and is formed
in the cell membrane of target cells, causing lysis [11].
DBA/2J mice are widely used as a model of inherited
glaucoma. DBA/2J mice develop hallmarks of human
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glaucoma including an age-related increase in IOP, and
an early insult to RGC axons at the optic nerve head
[12-14]. As in humans, lowering IOP lessens or prevents
glaucoma in DBA/2J mice [15-17]. Previous studies have
shown that activation of the complement cascade occurs
in both the retina and the optic nerve head in DBA/2J
glaucoma [4,18,19]. Hierarchical clustering of gene ex-
pression data predicts that activation of the complement
cascade is an early event in DBA/2J glaucoma [4]. High-
lighting the importance of the complement cascade,
DBA/2J mice mutant for the complement component
C1qa gene, an initiating factor in the classical pathway,
show a significant reduction in glaucomatous RGC loss
and optic nerve degeneration compared with normal
DBA/2J mice [4].
C5 is reported to play both beneficial and damaging
roles in neurodegenerative diseases including Alzheimer's
disease [20-22] and Huntington's disease [23]. C5 defi-
ciency also delays Wallerian degeneration and inhibits
monocyte recruitment after peripheral nerve injury [24].
Therefore, C5 would be predicted to affect glaucoma, but
functional experiments to determine its specific role in
glaucoma have not been performed. Contributing to the
lack of study of C5 in glaucoma is the fact that DBA/2J
mice are naturally deficient in C5 [25,26]. Thus, to deter-
mine the effects of C5 in glaucoma, we developed C5-suf-
ficient DBA/2J mice by transferring a functional C5 gene
from strain C57BL/6J. C5-sufficient DBA/2J mice develop
a more severe form of glaucoma than C5-deficient DBA/
2J mice indicating an important role for C5 in glaucoma.
Methods
Mouse strains, breeding, and husbandry
All experiments were performed in compliance with the
ARVO statement for use of animals in ophthalmic and vi-
sion research. All experiments involving animals were ap-
proved by The Jackson Laboratory Animal Care and Use
Committee. All mice were bred at the Jackson Laboratory
and housed with a 14-hour-light/10-hour-dark cycle, under
the same conditions as previously described [27]. To gener-
ate C5-sufficient DBA/2J mice (herein referred to as DBA/
2J.C5B6, official strain name DBA/2J.B6-Hc+/Sj), the inter-
val of mouse chromosome 2 containing a functional C5
gene was backcrossed to DBA/2J for 11 generations. Mice
heterozygous for the B6 region containing C5 were
intercrossed to generate cohorts of DBA/2J mice of all C5
genotypes (C5D2/D2, C5D2/B6 and C5B6/B6). There were no
observable differences between C5D2/B6 and C5B6/B6 mice,
thus unless otherwise stated, these are collectively referred
to as C5B6.
Determining the congenic interval in D2.C5B6 mice
The extent of the B6-derived region was analyzed after 11
generations of backcrossing using polymorphic markers
spanning the proximal portion of mouse chromosome 2
(identified using Ensembl and Mouse Genome Informat-
ics). Polymorphic markers included D2Mit296 (D2 = 144
bp, B6 = 154 bp), D2Mit367 (D2 = 162 bp, B6 = 149 bp),
D2Mit369 (D2 = 110 bp, B6 = 129 bp), D2Mit241 (D2 =
96 bp, B6 = 135 bp) and D2Mit376 (D2 = 86 bp, B6 = 92
bp). For each marker, DNA was amplified by PCR from
D2.C5B6, D2, and B6 mice under standard conditions.
Products were resolved in 3% agarose gels.
Iris disease and IOP measurement
In standard DBA/2J mice, glaucomatous IOP elevation
follows the onset of the iris disease [28]. Therefore,
when altering the genotype of DBA/2J mice, it is neces-
sary to evaluate both iris disease and IOP elevation. Iris
disease was followed in mice using a slit-lamp bio-
microscope as previously reported [29]. IOP measure-
ments were performed using the microneedle method as
previously described [30]. Ages and sample sizes are de-
tailed in the results and figure legends. Statistical ana-
lysis was performed using ANOVA (JMP statistical
package).
Tissue harvesting and processing
Eyes, with the intra-orbital portion of the optic nerve
still attached, were enucleated and fixed overnight in 4%
paraformaldehyde (PFA) at 4°C. The retro-orbital por-
tions of the optic nerve (to the chiasm) were carefully
removed from the underside of the brain and fixed in
4% PFA overnight. Eyes and optic nerves were stored in
0.5 mol/L phosphate buffer at 4°C.
Immunofluorescence and RGC quantification
For immunofluorescence, whole retinas were dissected
free, washed with 1X PBS-T (phosphate-buffered saline
with 0.5% Triton-X100), and incubated with monoclonal
antibodies against tubulin β-III (TUBB3; 1:500; Sigma-
Aldrich, St Louis, MO, USA) and rabbit polyclonal C5b-
9 (1:200; Calbiochem, San Diego, CA, USA) for 96 hours
at 4°C. After washing 3 times with PBS-T, the retinas
were incubated in the respective secondary antibodies
for 2 hours. The retinas were further washed in PBS-T and
mounted (Aqua Poly/Mount; Polysciences, Warrington,
PA, USA), and imaging was performed (Axio Imager;
Zeiss, Jena, Germany). For quantification of TUBB3-
immunolabeled RGCs, cuts were made in the retinas to
divide it into four equal quadrants, and two digital images
(350 × 350 μm) were taken of the peripheral retina in each
quadrant. Manual counts were performed using the cell
count tool from the Fiji software (http://imagej.nih.gov/ij).
The number of retinas per group is given in the Results
section and figure legends.
For immunofluorescence of the intra-orbital portion of
the optic nerve and optic nerve head, eyes with the
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intra-orbital nerve still attached were immersed in 30%
sucrose (until they sank), rinsed in 1 × PBS and frozen
in optical cutting temperature (OCT) compound. Eyes
were cut into 10 μm sections, and the central sections
containing optic nerve were stained with polyclonal
C5b-9 and monoclonal phosphorylated neurofilament
(pNF; 1:500, Dako, Glostrop, Denmark) as described
previously [4]. For each experiment, at least four sec-
tions from six eyes for each glaucoma severity for each
genotype were assessed. Imaging and photography was
performed on both an imaging microscope (Axio
Imager; Zeiss) microscope and a confocal microscope
(SP5; Leica, Heerbrugg, Switzerland).
Assessment of glaucomatous damage
Retro-orbital optic nerves (within 1 to 2 mm of the
orbit) were processed for plastic sectioning and para-
phenylenediamine (PPD) staining to differentiate seve-
rity of glaucoma, and analyzed as previously reported
[28,31]. Eyes had one of three damage levels: no or early
(NOE, <10% axons damaged/lost), moderate (< 50%
axons damaged/lost) or severe (> 50% axons damaged/
lost).
Results
D2.C5B6 mice develop a disease of the iris and a
glaucomatous IOP profile
DBA/2J (D2) mice do not express a functional C5 pro-
tein, owing to a frameshift mutation in the C5 gene
[26]. To determine the affect of a functioning C5 gene
on the progression of D2 glaucoma, the C5 allele
from C57BL/6J (B6) mice was backcrossed into the
DBA/2J strain (D2.C5B6) (Figure 1A). D2 mice develop
a secondary glaucoma as a result of an iris disease,
Figure 1 Progression of iris disease and intraocular pressure (IOP) profiles in DBA/2J and D2.C5B6 mice. (A) The congenic interval
surrounding C5 in D2.C5B6 mice determined using markers polymorphic between D2 and B6 (see Methods). The proximal and distal breakpoints
are indicated by the dotted line. The confirmed congenic interval from B6 is shown as a solid line. The size of the congenic interval is between
12 Mb and 19 Mb, which equates to less than 0.5% of the mouse genome. Analysis of known variations between D2 and B6 showed that C5 is
the only gene in this region that has a null mutation in D2 compared with B6. (B) Eye examinations with broad-beam illumination (top) and
transillumination (bottom) found no obvious differences in iris disease progression between D2.C5B6 and DBA/2J mice. (C) Age-dependent
elevation of IOP was found in both D2 and D2.C5B6 mice (red) compared with young D2 mice (black). Box plots were generated using JMP
version 7.0. The ends of each box represent the 75th and 25th percentile. The lines across the middle of each box indicate the median value. The
whiskers extending from either end indicate the extent of the data points. Values falling outside the whiskers are considered outliers. The green
diamonds indicate the mean and the 95% confidence interval.
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followed by IOP elevation. To determine whether a
functioning C5 gene had an effect on the iris disease,
detailed ocular examinations were performed on at least
20 D2 and 20 D2.C5B6 mice at 6, 8, 10, and 12 months of
age. Both D2 and D2.C5B6 mice developed the characte-
ristic iris disease (Figure 1B). No obvious differences in
the onset or progression of iris stromal atrophy (ISA) or
iris pigment dispersion (IPD) were seen between D2 and
D2.C5B6 mice (Figure 1B).
We next compared IOP levels between D2.C5B6 and
D2 mice (Figure 1C). In D2 mice, IOP first started to in-
crease in a significant number of eyes at 8 to 8.5 months
Figure 2 Glaucomatous neurodegeneration was more severe in D2.C5B6 mice. (A) Distributions of optic nerve damage showed a significant
increase in the number of eyes with moderate (MOD; <50% axons damaged/lost) and severe (SEV; >50% axons damaged/lost) glaucoma at 10.5
months in D2.C5B6 compared with normal D2 mice (P = 0.0001). There was no difference between D2 mice carrying one (D2.C5D2/B6) or two
functioning copies (D2.C5B6/B6) of the C5 gene. Number of eyes: 10.5 months; D2 = 54, D2.C5D2/B6 = 33, D2.C5B6/B6 = 22, D2.C5B6 (combined D2.
C5D2/B6 and D2.C5B6/B6) = 55. 12 months; D2 = 33, B6 (combined) = 25. NOE, no or early glaucoma (no detectable axon loss but some eyes may
have early molecular changes). (B) A summary of the optic nerve damage assessment shown in (A). At 10.5 months of age, 78% of eyes from D2.
C5B6 mice showed either MOD or SEV glaucoma compared with only 57% of D2 mice. C) Examples of NOE and SEV damaged nerves in D2 and
D2.C5B6. Scale bar = 25 μm.
Figure 3 Significant loss of retinal ganglion cells (RGCs) in both D2 and D2.C5B6 mice. (A) Tubulin β-III (TUBB3)-labeled RGCs were counted
in flat-mount retinas with no or early (NOE) or severe (SEV) glaucoma at 10.5 months of age for both DBA/2J and D2.C5B6 mice. RGC
degeneration matched the severity of optic-nerve degeneration in both groups. Eight retinas of each age/genotype were counted. (B) Example
images of TUBB3-labeled RGCs in flat-mount retinas with NOE and SEV glaucomatous damage in D2 and D2.C5B6. Scale bar = 20 μm.
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of age and was increased in many eyes at 10.5 months of
age [31]. Therefore, IOP levels were measured at these
key ages. For both D2.C5B6 and D2 mice, IOP levels
were higher than those in young D2 controls. There was
no significant difference between the IOP profiles of D2.
C5B6 and D2 mice at 8.5 months of age (P = 0.23),
suggesting that C5 sufficiency does not affect the onset
of IOP increase. However, at 10.5 months of age, IOP
levels were significantly lower in D2.C5B6 mice com-
pared with D2 mice (P = 0.003). This difference suggests
that, although D2.C5B6 mice had a glaucomatous IOP
profile (as judged by a significant elevation in IOP levels
in D2.C5B6 mice at 8.5 (P = 0.002) and 10.5 months of
age (P< 0.0001) compared with DBA/2J control mice at
4.0 months), C5 sufficiency may affect the extent of IOP
elevation in D2.C5B6 mice.
More D2.C5B6 mice develop severe glaucoma at an earlier
age than D2 mice
In our colony, glaucomatous optic nerve degeneration in
D2 mice is typically observed between 10 and 12 months
of age [1,31]. D2.C5B6 mice showed a significant increase
in the number of eyes with severe glaucoma at 10.5
months of age (69%) compared with normal D2 eyes
(38%, P = 0.0001) (Figure 2). At 12 months of age, the
number of D2.C5B6 eyes with severe glaucoma was not
significantly different to normal D2 eyes of the same age
(76% compared with 67%, P = 0.09).
Previous studies have separated RGC axon degener-
ation in the optic nerve from the death of RGC somas.
For instance, in D2 mice that are deficient for the pro-
apoptotic gene BAX, optic nerves degenerate to the
same extent as in normal BAX-sufficient D2 mice, but
Figure 4 Membrane attack complex (MAC) deposition in dystrophic axons during early glaucoma in D2.C5B6 optic nerves. (A-C) As expected,
no MAC deposition was seen in D2 optic nerve axons at 10.5 months of age. (D-F) However, MAC deposition (as judged by the presence of anti-C5b-9)
was found in the optic nerve head from D2.C5B6 mice with no or early (NOE) glaucoma. (G-I) High magnification views from D-F, showing some
dystrophic neurites were labeled by anti-C5b-9, indicating deposition of MAC in these degenerative structures (arrows). Scale bar = 20 μm.
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RGC soma survive [32]. Therefore, to determine the ex-
tent of RGC somal loss in D2.C5B6 mice, retinal flat
mounts from D2.C5B6 and D2 eyes with no detectable
glaucoma (NOE) and severe glaucoma were labeled with
TUBB3, and the TUBB3-positive cells in the ganglion
cell layer were counted (see Methods). Both D2.C5B6
and D2 eyes with severe glaucoma showed significant
loss of RGCs (Figure 3). Collectively, our data showed
that a functional C5 gene significantly exacerbates both
optic-nerve degeneration and RGC somal loss in DBA/
2J mice.
MAC deposition on RGC axons and soma very early in
glaucoma
C5 has been shown to play multiple roles in neurodegen-
erative diseases and after neuronal injury [21,23,33-35].
The C5 protein is cleaved by C5 convertases to produce
C5a and C5b. C5a plays an important role in inflamma-
tion, while C5b is involved in cell lysis [10]. To begin to
determine how a functioning C5 protein may contribute
to more severe glaucoma in D2.C5B6 mice, optic nerves
were analyzed with anti-C5b-9, an antibody that recog-
nizes a functioning MAC. In D2.C5B6 eyes with early glau-
coma but no detectable axon loss, MAC deposition was
found in RGC axonal swellings (or dystrophic neurites) in
the optic nerve (Figure 4). Dystrophic neurites are an early
sign of RGC axon damage in the optic nerve head in glau-
coma [12]. As expected, C5b-9 was not seen in C5-
deficient D2 mice (Figure 4A-C).
Previous work has also shown that the MAC can be
deposited on neuronal bodies after injury [20,21,23].
Therefore, to determine whether a functioning C5 gene
results in MAC deposition in RGC soma in glaucoma,
we localized C5b-9 in retinas from D2.C5B6 eyes with
early glaucoma. To identify RGCs, retinas were co-
labeled with anti-TUBB3 antibody. Interestingly, in D2.
C5B6 eyes with no detectable optic nerve damage behind
the eye, RGCs showed significant levels of MAC depos-
ition (Figure 5). Again, no MAC staining was found in
glaucomatous retinas from C5-deficient D2 mice. To-
gether, these experiments support a role for C5 and the
MAC in the early stages of glaucomatous RGC loss in
glaucoma.
Discussion
Previous work has shown increased expression of com-
ponents of the classical complement pathway in glau-
coma [1,4-7,36]. Glaucomatous neurodegeneration was
reduced in C1qa-deficient DBA/2J mice, indicating a
crucial role of this protein and the complement cascade
in general in glaucoma [4]. It is thought that the expres-
sion of C1qa in either RGCs and/or microglia/mo-
nocytes mediates the glaucomatous damage to RGCs,
although C1qa has also been reported to be expressed in
other retinal cell types such as photoreceptors [37]. In
this study, we show for the first time that a second key
component of the complement cascade, C5, modulates
the progression of RGC loss in DBA/2J glaucoma. Our
results show that C5 deficiency protects normal D2 mice
from glaucoma, with C5 sufficiency rendering mice
prone to develop a more severe form of glaucoma.
Similar to other complement proteins, C5 is present in
multiple locations and cell types during glaucoma, in-
cluding the retina and the optic nerve head, and it could
Figure 5 Membrane attack complex (MAC) deposition in retinal ganglion cell (RGC) soma in D2.C5B6 mice. (A-C) D2 retinas did not show
any MAC staining. (D-F) Significant deposition of MAC was evident in RGCs from 10.5-month-old D2.C5B6 eyes with no or early (NOE) glaucoma.
Scale bar = 20 μm.
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contribute to glaucoma in multiple ways including
modulation of IOP elevation. For instance, C1qa and C3
have been shown to be necessary for synaptic pruning in
the retina during development, and may be necessary for
RGC synapse remodeling early in glaucoma [9]. C1qa
may also mediate ribbon synapse remodeling in photore-
ceptors in DBA/2J mice [37], although we have not
found any photoreceptor changes in our DBA/2J colony
[31]. Further work is needed to determine the exact role
(s) of C5 in synapse remodeling and other crucial pro-
cesses in glaucoma.
The C5 protein can be converted into two active pep-
tides, C5a, a proinflammatory anaphylatoxin, and C5b, a
key component in the formation of the MAC [10].
Therefore, a functioning C5 gene may provoke either a
proinflammatory effect, the formation of the MAC, or
both. C5a is a potent proinflammatory molecule in-
volved in immune-cell recruitment and entry of cells
into tissues from the vasculature [38-40], two events we
have shown to be important in early stages of glaucoma
[41]. It has also been shown that C5a can act directly on
neurons through the C5a receptor (C5aR) [42,43]. Previ-
ous studies have reported that C5a can exert a protective
effect on neurons expressing C5aR after neuronal ex-
citotoxicity [42,44]. Interestingly, in our microarray stud-
ies, C5aR was increased in the early stages of glaucoma
in both the retina and the optic nerve head [4,45]. How-
ever, the C5-sufficient D2 mice were more prone to se-
vere glaucoma compared with the C5-deficient DBA/2J
mice, implying either a different role for C5a/C5aR, or a
greater, more damaging, contribution from C5b.
Generation of C5b is a necessary step in the formation of
the MAC. We found significant MAC deposition in glau-
comatous RGCs, and dystrophic neurites in optic nerves of
D2.C5B6 mice. MAC deposition in RGCs has also been
reported in human glaucoma and in other experimental
models [5,46]. Studies have also identified significant MAC
deposition in other neurodegenerative diseases such as
traumatic brain injury (TBI) [34,47], acute brain ischemia
[35], peripheral nerve injury [48], Alzheimer’s disease
[20-22,49], and Huntington's disease [23]. Our study sug-
gests that MAC deposition may be a damaging event in
glaucoma. This is also supported by studies that show that
an increase in MAC deposition (using mice deficient for
the MAC inhibitor CD59a) can have adverse neuropatho-
logical outcomes in experimental models of TBI [47],
peripheral nerve injury [50], and tau pathology [51].
Therefore, although we cannot exclude a contribution of
C5a, it is likely that MAC deposition is a major contribu-
tor to the increase in glaucoma severity in D2.C5B6 mice.
Further work using specific ablation of either C5a or C5b
in specific cell types is needed to confirm this.
In summary, we have demonstrated that the down-
stream components of the complement cascade have a
damaging role in glaucoma, and that the natural C5 defi-
ciency protects D2 mice from severe glaucoma. This im-
plies that a functional C5 protein affects RGC loss in
human glaucoma, and that inhibition of C5 may be a
useful target for treatment. Given that most humans
have a functional C5 gene, C5-sufficient D2 mice may
more closely model human glaucoma, and D2.C5B6 mice
are therefore an important new strain for understanding
the role of the complement cascade in glaucoma.
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